Pettitt, A., Jackson, R., Carruthers, S., Dodd, J., Dodd, S., Oates, M., . . . Hillmen, P. (2012). Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: Final results of the national cancer research institute CLL206 trial.
Chicago Style (17th ed.) CitationPettitt, A., et al. Alemtuzumab in Combination with Methylprednisolone Is a Highly Effective Induction Regimen for Patients with Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. 2012.
MLA (9th ed.) CitationPettitt, A., et al. Alemtuzumab in Combination with Methylprednisolone Is a Highly Effective Induction Regimen for Patients with Chronic Lymphocytic Leukemia and Deletion of TP53: Final Results of the National Cancer Research Institute CLL206 Trial. 2012.